Abstract: The invention relates to a process for reducing the minimum inhibitory concentration (MIC) of a biocide against at least one strain of bacteria and/or at least one strain of yeast and/or at least one strain of mould in an aqueous preparation. The invention further relates to the use of a water soluble source of lithium ions for reducing the minimum inhibitory concentration (MIC) of a biocide against at least one strain of bacteria and/or at least one strain of yeast and/or at least one strain of mould in an aqueous preparation.

Abstract: Disclosed herein are biomaterial implants, medical devices, or bioprostheses wherein a surface or part thereof is coated with a nanoreservoir comprising a hydrophilic polymer or copolymer backbone crosslinked to a second polymer comprising a hydrophilic backbone and one or more reactive moieties, wherein the nanoreservoir further comprises one or more bioactive molecules, therapeutic molecules, or drugs.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: Disclosed herein are compositions including diphenhydramine, or a pharmaceutically acceptable salt thereof, and a liquid vehicle. The compositions may be administered intranasally to patients in need of diphenhydramine. The compositions provide increase plasma and brain concentrations relative to orally administered compositions, but without the limitations associated with intravenously administered compositions.

Abstract: The present invention relates to a process for treating human keratin fibres such as the hair, which comprises: i) a step of applying to the human keratin fibres a composition comprising: —at least one plant wax: —at least 60% by weight of water relative to the total weight of the composition; ii) followed by a step of heating the keratin fibres by means of a heating appliance at a temperature ranging from 80° C. to 160° C., preferably from 110° C. to 50° C., more preferably from 120° C. to 150° C., which is moved along the fibres, iii) optionally followed by a step of rinsing the keratin fibres.

Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Abstract: An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.

Abstract: Method for treating hair comprising the successive application onto hair of polymeric layers which can be removed to a large extent or even totally in an easy manner upon request of the user by using a cationic surfactant.

Abstract: Exemplary embodiment of the present disclosure are directed towards a stable nanodispersion comprising an aqueous dispersion medium, a dispersed phase, a surface active agent and optionally, an additive, wherein the aqueous dispersion medium comprises of a nanodispersion stabilizing vehicle base component, wherein the nanodispersion stabilizing vehicle base component improves long term physical stability of the nanodispersion with or without particle size reduction, wherein the dispersed phase comprises of a bioactive compound and wherein the bioactive compound is a lipophilic and hydrophobic. Another exemplary embodiment of the present disclosure is directed towards a method of preparation of such stable nanodispersion.

Abstract: The present invention relates to a composition, preferably a cosmetic composition, and more preferably a skin cosmetic composition, comprising: (a) at least one particle, comprising at least one cationic polymer, at least one anionic polymer and at least one non-polymeric base having two or more pKb values or salt(s) thereof; and (b) at least one physiologically acceptable volatile medium. The composition according to the present invention is stable, and can have a variety of cosmetic functions.

Abstract: The present invention comprises compounds of formula (I): where R1 may be PEG or other polymeric moieties. For example, R1 may be repeating PEG units —(CH2—CH2—O)n—, wherein n=1-455. R1 may also be other polymeric moieties of varying sizes and structures, for example, R1 may be poly(glycolide), poly(lactic acid), poly(lactide), poly(caprolactone), poly(lactide-co-caprolactone), poly(lactide-co-glycolide), or poly(lactic acid)-butanol. One or more embodiments of the invention may also relate to injectable pharmaceutical compositions comprising polymer conjugated monomethyl fumarate, and methods for treating relapsing-remitting multiple sclerosis and psoriasis.

Abstract: Provided herein are polymers, pH-sensitive polymers and/or linkers; conjugates comprising said polymers and/or linkers, optionally, coupled to one or more agents and/or targeting moieties; and particles (e.g., nanoparticles comprising the aforesaid polymers, linkers and/or conjugates), which can be used to enhance the delivery and/or efficacy of one or more agents in a subject.

Abstract: Aspects of the present invention are directed to an oral dosage form comprising a core containing one more active ingredients and a fast-release exterior coating. The fast release exterior coating includes a water soluble polymer; a saccharide or sugar alcohol, or a combination thereof, and a flavoring. The flavoring may be a warming sensate that is released in the oral cavity of the user after inserting the dosage form in his or her mouth.

Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Abstract: The invention provides ophthalmic compositions comprising about 0.1 % (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.

Abstract: A method is described for producing a dosage form. Also described, are granules and tablets obtained by the method. The use of a surface-reacted calcium carbonate in such a method, a dosage form comprising the granules, the use of the granules, or the tablets and/or capsules, or the dosage form in a pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product as well as pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product including such granules, or the tablets and/or capsules, or the dosage form are also described.

Abstract: The present invention relates to a composition according to the present invention comprises: (a) at least one particle comprising at least one cationic polymer, at least one anionic polymer, and at least one non-polymeric acid having two or more pKa values or salt(s) thereof; and (b) at least one physiologically acceptable volatile medium. The composition according to the present invention is stable, and can have a variety of cosmetic functions. For example, the composition according to the present invention can prepare a film which can have cosmetic effects such as absorbing or adsorbing malodor, changing the appearance of a keratin substrate such as skin, changing the feel to the touch of the keratin substrate, and/or protecting the keratin substrate from, for example, dirt or pollutants.

Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Abstract: A method is described for producing a dosage form and granules including surface-reacted calcium carbonate. Also described, are tablets and/or capsules obtained by the method. Methods using such a surface-reacted calcium carbonate, and a dosage form comprising the granules are also described. Further, methods of using the granules, or the tablets and/or capsules, or the dosage form in a pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product are also described. A pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product including the granules, or the tablets and/or capsules, or the dosage form are also described.

Abstract: A composition is for use as a medicament. The composition contains nanoparticles, wherein the nanoparticles contain a polymer selected from the group consisting of PLGA, PLA, PGA, PCL and poly(meth)acrylates, or a lipid. Further, the composition may contain nanoparticles made of a polymer selected from PLGA, amino alkyl methacrylate copolymers, methacrylic acid copolymers, methacrylic ester copolymers, and ammonio alkyl methacrylate copolymers.